- Conditions
- SARS-CoV Infection, Covid19
- Interventions
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), Placebo (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)
- Biological · Other
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 33,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 144
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 110 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–34
of 34
matching trials from the live ClinicalTrials.gov search.
- Conditions
- COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection
- Interventions
- protein subunit: Novavax COVID-19 vaccine, Pfizer mRNA COVID-19 vaccine
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Low dose RSV F Antigen, High dose RSV F Antigen, Dose 1 of Aluminum Adjuvant, Dose 2 of Aluminum Adjuvant, Dose 3 of Aluminum Adjuvant, Dose 4 of Aluminum Adjuvant, Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 720 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 10
- States / cities
- Walnut Creek, California • Stockbridge, Georgia • Boise, Idaho + 7 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28), High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28), Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • Melbourne, Florida • Dallas, Texas + 1 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- RSV-F Vaccine, Saline Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 1,599 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 10
- States / cities
- Redding, California • Stockbridge, Georgia • Lenexa, Kansas + 7 more
- Conditions
- COVID-19
- Interventions
- XBB.1.5 Vaccine (Booster), XBB.1.5 Vaccine (single dose)
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 54 Years
- Enrollment
- 660 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 30
- States / cities
- Mobile, Alabama • Sacramento, California • Colorado Springs, Colorado + 26 more
- Conditions
- COVID-19
- Interventions
- NVX-CoV2373 (5μg), NVX-CoV2601(5μg), NVX-CoV2601(35μg), NVX-CoV2601(50μg), Bivalent BA.4/5
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 994 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 50
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Banning, California + 44 more
- Conditions
- Pandemic Influenza
- Interventions
- H5N1 VLP Vaccine, Placebo
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 230 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2008
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- COVID-19
- Interventions
- SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo
- Biological · Other
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 6 Months to 11 Years
- Enrollment
- 3,600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 47
- States / cities
- Little Rock, Arkansas • Anaheim, California • Bellflower, California + 41 more
- Conditions
- COVID-19
- Interventions
- NVX-CoV2601 co-formulated Omicron XBB.1.5 SARS-CoV-2 rS vaccine, Prototype/XBB.1.5 Bivalent Vaccine (5 µg)
- Biological
- Lead sponsor
- Novavax
- Industry
- Eligibility
- 11 Years to 18 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 20
- States / cities
- Davie, Florida • Jacksonville, Florida • Miami, Florida + 17 more